Liu et al. suggested that COX-2 inhibitors inhibited angiogenesis after chemotherapy, which was correlated with the inhibition of VEGF and platelet-derived factors.60 This may be a potential cause of the increased incidence of leukopenia and thrombocytopenia.61 Similarly, celecoxib combined with TKIs increased anemia, leukopenia, cardiovascular toxicity and other side effects. The gene discussed is VEGFA; the disease is Thrombocytopenia.